| Osimertinib studied in …STUDIED_INderived200 of 223show all (up to 200) |
|---|
| → studied in | NCT04487080Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647122Phase 1 · active not recruiting First in Human Study of AZD9592 in Solid Tumors · 223 trials list this drug (123 active) | — | — | Head and Neck Neoplasm,Solid Neoplasm,Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07155187Phase 2/Phase 3 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03191149Phase 2 · recruiting Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03381274Phase 1/Phase 2 · active not recruiting Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618287Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors · 223 trials list this drug (123 active) | — | — | Malignant Breast Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009836Phase 3 · active not recruiting Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03891615Phase 1 · terminated Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410043Phase 2 · active not recruiting Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05017025Phase 1/Phase 2 · completed Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03831932Phase 1/Phase 2 · active not recruiting Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486833Phase 1/Phase 2 · recruiting Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04780568Phase 1 · recruiting Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06303167Phase 2 · active not recruiting Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) · 223 trials list this drug (123 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02511106Phase 3 · active not recruiting AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04410796Phase 2 · recruiting Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06014827Phase 2 · suspended Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07640789Phase 3 · recruiting A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03040973Phase 2 · active not recruiting Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04351555Phase 3 · active not recruiting A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06538038active not recruiting Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07738172Phase 3 · recruiting Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05801029Phase 2 · active not recruiting A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04035486Phase 3 · active not recruiting A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06507306Phase 1 · active not recruiting A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies · 223 trials list this drug (123 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07622186Phase 2 · recruiting A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07079475Phase 1/Phase 2 · recruiting Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 223 trials list this drug (123 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133546Phase 2 · completed Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350097Phase 3 · recruiting Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05948813Phase 2 · recruiting TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases · 223 trials list this drug (123 active) | — | — | Brain Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07680790Phase 3 · not yet recruiting Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03940703Phase 2 · completed A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07329322Phase 2 · recruiting Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06194448Phase 2 · active not recruiting To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05624996Phase 3 · recruiting Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02971501Phase 2 · active not recruiting Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06970639Phase 3 · recruiting A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04769388Phase 2 · completed Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03392246Phase 2 · active not recruiting A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04085315Phase 1 · completed Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05261399Phase 3 · active not recruiting Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment · 223 trials list this drug (123 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05401110Phase 1 · recruiting Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05546866Phase 2 · active not recruiting Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03521154Phase 3 · active not recruiting A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05526755Phase 2 · active not recruiting A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07642024Phase 2/Phase 3 · recruiting A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496663Phase 1 · active not recruiting Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04563871Phase 2 · completed Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05142189Phase 1 · recruiting Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285671Phase 1/Phase 2 · active not recruiting Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07669779Phase 2 · recruiting A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07535437Phase 1/Phase 2 · recruiting A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06670196Phase 3 · active not recruiting A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05629234Phase 3 · active not recruiting Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) · 223 trials list this drug (123 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315113Phase 1 · recruiting Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03567642Phase 1 · active not recruiting A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05120349Phase 3 · active not recruiting A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07153055Phase 1/Phase 2 · recruiting Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06741085Phase 2 · recruiting A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02503722Phase 1 · active not recruiting Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005102Phase 2/Phase 3 · recruiting A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05642572Phase 2 · recruiting Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07612137Phase 1/Phase 2 · not yet recruiting Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors · 223 trials list this drug (123 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07375316Phase 2 · recruiting A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04141644Phase 1 · active not recruiting Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06417814Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06486142Phase 3 · recruiting EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07376382Phase 3 · not yet recruiting A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591002Phase 2 · recruiting Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03122717Phase 1/Phase 2 · active not recruiting Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586453Phase 2 · active not recruiting Osimertinib In EGFR Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02664935Phase 2 · completed National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Adenocarcinoma,Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06630325Phase 2 · terminated A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer · 223 trials list this drug (123 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03778229Phase 2 · active not recruiting Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib · 223 trials list this drug (123 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01802632Phase 1/Phase 2 · completed AZD9291 First Time In Patients Ascending Dose Study · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06838273Phase 3 · recruiting A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07323641Phase 2 · recruiting Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03909334Phase 2 · active not recruiting Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 223 trials list this drug (123 active) | — | — | Malignant Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479306Phase 1 · completed Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07295821Phase 2 · recruiting Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05785741Phase 1/Phase 2 · recruiting A Study of DB-1310 in Advanced/Metastatic Solid Tumors · 223 trials list this drug (123 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665206Phase 1/Phase 2 · recruiting Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors · 223 trials list this drug (123 active) | — | — | Adult Solid Neoplasm,Malignant Mesothelioma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762199Phase 1 · recruiting MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03433469Phase 2 · active not recruiting Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07491211active not recruiting Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05166616Phase 1 · active not recruiting Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04868877Phase 1/Phase 2 · active not recruiting Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination · 223 trials list this drug (123 active) | — | — | Malignant Gastric Neoplasm,Esophageal Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02917993Phase 1/Phase 2 · completed An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04184921Phase 2 · completed Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05816252Phase 2 · active not recruiting A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04743505Phase 1/Phase 2 · active not recruiting Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02411448Phase 3 · active not recruiting A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05089916Phase 2 · active not recruiting Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02442349Phase 2 · completed Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810807Phase 1 · completed Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07256509Phase 2 · not yet recruiting A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05103605active not recruiting Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07206498Phase 1/Phase 2 · recruiting A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07058519Phase 2 · recruiting A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02157883Phase 1 · completed Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954871Phase 1 · completed Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03667820Phase 2 · active not recruiting Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04695925Phase 3 · active not recruiting Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations · 223 trials list this drug (123 active) | — | — | Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215951Phase 2 · terminated Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04001777Phase 1 · active not recruiting A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06304441NA · recruiting Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020769Phase 2/Phase 3 · active not recruiting SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05880706Phase 2 · active not recruiting A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07177092Phase 2 · not yet recruiting Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02099058Phase 1 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04721015Phase 1 · active not recruiting Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07038460Phase 2 · not yet recruiting A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04676477Phase 1 · active not recruiting HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06574347Phase 2 · recruiting Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755102early Phase 1 · completed A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. · 223 trials list this drug (123 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06498986Phase 2 · recruiting A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06895928Phase 2 · recruiting A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors · 223 trials list this drug (123 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720976Phase 1/Phase 2 · completed JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors · 223 trials list this drug (123 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06908772Phase 2/Phase 3 · not yet recruiting Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03543683Phase 2 · completed Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281406Phase 2 · recruiting Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06827145Phase 2 · active not recruiting Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03414814Phase 2 · completed Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862780Phase 1 · terminated (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC · 223 trials list this drug (123 active) | — | — | Neoplasm,Neoplasm by Site,Respiratory System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04233021Phase 2 · completed Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03944772Phase 2 · active not recruiting Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02841579Phase 2 · completed Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06752408Phase 2 · not yet recruiting Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06735391Phase 3 · recruiting A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06709274NA · not yet recruiting Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228015Phase 1 · terminated Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors · 223 trials list this drug (123 active) | — | — | Solid Neoplasm,Adult Solid Neoplasm,Pleural Malignant Mesothelioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 223 trials list this drug (123 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03732352Phase 2 · completed 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma · 223 trials list this drug (123 active) | — | — | Glioblastoma,Supratentorial Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02094261Phase 2 · completed Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03769103Phase 2 · active not recruiting Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322890Phase 2 · recruiting Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03239340Phase 2 · completed A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02454933Phase 3 · completed Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520778Phase 1 · completed Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06557096early Phase 1 · not yet recruiting CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04770688Phase 1/Phase 2 · completed Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib · 223 trials list this drug (123 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545710Phase 2 · active not recruiting Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06362980Phase 1 · unknown A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02954523Phase 1/Phase 2 · terminated Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04908956Phase 2 · terminated Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06093503Phase 3 · withdrawn Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02759835Phase 2 · completed Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib · 223 trials list this drug (123 active) | — | — | Lung Neoplasm,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03497767Phase 2 · completed A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06436144Phase 2 · not yet recruiting Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810066Phase 2 · completed Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06383728Phase 2 · recruiting Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03804580Phase 2 · unknown First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06391944Phase 2 · active not recruiting JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06380348Phase 3 · not yet recruiting JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04772235Phase 1 · unknown Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06323148Phase 3 · not yet recruiting Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06319950Phase 2 · not yet recruiting High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03535363Phase 1 · completed Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04816214Phase 3 · terminated Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05163249Phase 2 · unknown Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02789345Phase 1 · completed A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05382728Phase 3 · recruiting Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02163733Phase 1 · completed Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05011487Phase 2 · recruiting Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05421936suspended Osimertinib for NSCLC With Uncommon EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06142617Phase 2 · not yet recruiting A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965701completed First Line Osimertinib in the Real World: an Inter-regional Prospective Study · 223 trials list this drug (123 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03434418Phase 2 · completed A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06067776Phase 1 · not yet recruiting Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02803203Phase 1/Phase 2 · completed Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06018688Phase 2 · unknown Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04959981Phase 1 · completed A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989115Phase 1/Phase 2 · completed Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC · 223 trials list this drug (123 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05153408Phase 1 · terminated (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC · 223 trials list this drug (123 active) | — | — | Neoplasm,Neoplasm by Site,Respiratory System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05489731Phase 1 · unknown VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498389Phase 1/Phase 2 · unknown EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179890completed The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib · 223 trials list this drug (123 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455829Phase 1/Phase 2 · completed G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974879Phase 2 · unknown Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02504346Phase 2 · unknown AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05785208Phase 4 · unknown Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04391283unknown First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05693090Phase 1 · withdrawn Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04811001Phase 2 · unknown Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463525Phase 1 · completed Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05686434Phase 2 · recruiting Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784599Phase 2 · terminated T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583409NA · unknown SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05513664unknown Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507606Phase 2 · unknown Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458726Phase 2 · unknown Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03790397completed Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03255083Phase 1 · terminated DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132777Phase 2 · unknown Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03219970completed Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting. · 223 trials list this drug (123 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02736513Phase 2 · unknown Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases · 223 trials list this drug (123 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |